In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen and Celltech develop Crohn's disease drug; development halted

Executive Summary

Biogen and Celltech will research, develop, manufacture, and market CDP571, Celltech's humanized anti-TNF-alpha antibody, which is in Phase III trials for Crohn's disease. The companies will also test the compound for other inflammatory indications, such as psoriasis.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register